Clinical Trial Update: A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 [Phase 2]

View source ↗

Summary

Phase 2 study of VGX-3100 DNA vaccine with electroporation in cervical intraepithelial neoplasia 2/3 or 3 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• VGX-3100

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Cervical Intraepithelial Neoplasia | Phase 2 | Status: COMPLETED